LPA and angina pectoris: In the case of the JUPITER study [14] the authors concluded that among white participants treated with potent statin therapy, Lp(a) concentrations (at baseline and on-statin) were a significant determinant of residual risk with respect to CVD events; and in the PRIME study [34] that increased baseline Lp(a) levels (considered as the Lp(a) cholesterol content) were significantly associated with the risk for MI and angina pectoris, especially in men with high LDL-C.